Postdoctoral position is available in the field of pharmacogenomics. The long term goal is to devise treatment regimens for acute lymphoblastic leukemia (ALL) with improved efficacy and less toxicity. The discovery work in the lab focuses on elucidation of the genetic and treatment-related determinants of ALL outcome phenotypes (relapse and adverse effects such as asparaginase-induced pancreatitis, allergy, and hepatic toxicity, and glucocorticoid-induced osteonecrosis). Genome-wide approaches are used in the clinic, and candidate genes are further explored in mechanistic follow-up studies in preclinical or clinical models. The primary preclinical models include murine models of ALL efficacy and of drug-induced adverse effects, superimposed on murine host genetic backgrounds that mimic host genetic variability observed in patients with ALL. Clinical and translational studies are performed in the context of well-controlled clinical trials, with substantial collaborations with statisticians and clinicians at St. Jude and with the Children’s Oncology Group, CALGB/Alliance, and ECOG/ACRIN.
In addition, there are opportunities to engage in our programs for clinical implementation of pharmacogenetics, both locally at St. Jude (www.stjude.org/pg4kds) and as part of a leading international consortium (www.cpicpgx.org) as part of the NIH Pharmacogenomics Research Network (www.pgrn.org).
The candidate should have laboratory expertise in a relevant area, although candidates with a strong statistical genetics and/or computational background will also be considered.